Cargando…
CoViD-19 Immunopathology and Immunotherapy
New evidence on the T-cell immuno-pathology in patient’s with Corona Virus Disease 2019 (CoViD-19) was reported by Diao et al. in MedRxiv (doi: 10.1101/2020.02.18.20024364) [1]. It reports observations on 522 patients with confirmed CoViD-19 symptomatology, compared to 40 control subjects. In brief,...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Biomedical Informatics
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7147500/ https://www.ncbi.nlm.nih.gov/pubmed/32308263 http://dx.doi.org/10.6026/97320630016219 |
_version_ | 1783520433141710848 |
---|---|
author | Chiappelli, Francesco Khakshooy, Allen Greenberg, Gillian |
author_facet | Chiappelli, Francesco Khakshooy, Allen Greenberg, Gillian |
author_sort | Chiappelli, Francesco |
collection | PubMed |
description | New evidence on the T-cell immuno-pathology in patient’s with Corona Virus Disease 2019 (CoViD-19) was reported by Diao et al. in MedRxiv (doi: 10.1101/2020.02.18.20024364) [1]. It reports observations on 522 patients with confirmed CoViD-19 symptomatology, compared to 40 control subjects. In brief, notable T cytopoenia was recorded by flow cytometry in the CD4+ and the CD8+ populations, which were significantly yet inversely correlated with remarkably increased serum levels of the pro-inflammatory cytokines IL-6, IL-10 and TNF-a. Flow cytometry established a progressive increase in the expression of programmed cell death marker-1 (PD-1) and T cell immunoglobulin and mucin domain 3 (Tim-3) as patients (n=14) deteriorated from prodromal to symptomatic CoViD-19 requiring intensive care. Here, we interpret these observations of Diao et al from our current understanding of T cell immunophysiology and immunopathology following an immune challenge in the form of sustained viral infection, as is the case in CoViD-19, with emphasis on exhausted T cells (Tex). Recent clinical trials to rescue Tex show promising outcomes. The relevance of these interventions for the prevention and treatment of CoViD-19 is discussed. Taken together, the data of Diao et al could proffer the first glimpse of immunopathology and possible immunotherapy for patients with CoViD-19. |
format | Online Article Text |
id | pubmed-7147500 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Biomedical Informatics |
record_format | MEDLINE/PubMed |
spelling | pubmed-71475002020-04-17 CoViD-19 Immunopathology and Immunotherapy Chiappelli, Francesco Khakshooy, Allen Greenberg, Gillian Bioinformation Editorial New evidence on the T-cell immuno-pathology in patient’s with Corona Virus Disease 2019 (CoViD-19) was reported by Diao et al. in MedRxiv (doi: 10.1101/2020.02.18.20024364) [1]. It reports observations on 522 patients with confirmed CoViD-19 symptomatology, compared to 40 control subjects. In brief, notable T cytopoenia was recorded by flow cytometry in the CD4+ and the CD8+ populations, which were significantly yet inversely correlated with remarkably increased serum levels of the pro-inflammatory cytokines IL-6, IL-10 and TNF-a. Flow cytometry established a progressive increase in the expression of programmed cell death marker-1 (PD-1) and T cell immunoglobulin and mucin domain 3 (Tim-3) as patients (n=14) deteriorated from prodromal to symptomatic CoViD-19 requiring intensive care. Here, we interpret these observations of Diao et al from our current understanding of T cell immunophysiology and immunopathology following an immune challenge in the form of sustained viral infection, as is the case in CoViD-19, with emphasis on exhausted T cells (Tex). Recent clinical trials to rescue Tex show promising outcomes. The relevance of these interventions for the prevention and treatment of CoViD-19 is discussed. Taken together, the data of Diao et al could proffer the first glimpse of immunopathology and possible immunotherapy for patients with CoViD-19. Biomedical Informatics 2020-03-31 /pmc/articles/PMC7147500/ /pubmed/32308263 http://dx.doi.org/10.6026/97320630016219 Text en © 2020 Biomedical Informatics http://creativecommons.org/licenses/by/3.0/ This is an Open Access article which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. This is distributed under the terms of the Creative Commons Attribution License. |
spellingShingle | Editorial Chiappelli, Francesco Khakshooy, Allen Greenberg, Gillian CoViD-19 Immunopathology and Immunotherapy |
title | CoViD-19 Immunopathology and Immunotherapy |
title_full | CoViD-19 Immunopathology and Immunotherapy |
title_fullStr | CoViD-19 Immunopathology and Immunotherapy |
title_full_unstemmed | CoViD-19 Immunopathology and Immunotherapy |
title_short | CoViD-19 Immunopathology and Immunotherapy |
title_sort | covid-19 immunopathology and immunotherapy |
topic | Editorial |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7147500/ https://www.ncbi.nlm.nih.gov/pubmed/32308263 http://dx.doi.org/10.6026/97320630016219 |
work_keys_str_mv | AT chiappellifrancesco covid19immunopathologyandimmunotherapy AT khakshooyallen covid19immunopathologyandimmunotherapy AT greenberggillian covid19immunopathologyandimmunotherapy |